same ingredient at the same strength, to be marketed both Rx and OTC, provided that there are different indications for them?"
Botstein: There are some examples of drugs where that's true already, prescrip tion and over-the-counter marketing, and I would envision that it would continue to be the same in the future for very rare circumstances although it's been very con troversial in-house for us. There are some people who object very strongly to doing that. One example is Potassium Iodide, which is available prescription as an IV expectorant and available OTC as an oral liquid for radiation blocking-two totally absolutely different uses exist for Rx and OTC products containing the identical in gredient. In that case, we certainly can't have the IV expectorant available over the counter, and neither is it practical to have the radiation protection blocking form available prescription because, when you need it in case of an emergency, it's im practical to get individual prescriptions for large numbers of people.
Cooley: "You recommended early meet ings with the FDA on NDA switches. Would you recommend the same thing for monographs -early meetings?"
Dr William E. Gilbertson: Yes, I think
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Panelists: Cooley, Gilbertson, Botstein, Palmer that's very important. Extremely impor tant when you begin to think that you want to switch a drug. It might be worth adding-Dr Botstein and I were talking earlier that we've established internally an OTC Task Force which-Dr Rheinstein, Dr Botstein, Dr Temple, myself, and oth ers are on this internal Task Force. We ha ven't had that type of thing before, but we're going to try to keep close together communication-wise on future switches, because people do shop around; they'll come to our office, they'll go to another Division office. I think it's important that we have a consistent Agency policy on these things and that we all be aware of what drugs are being switched. One of the things we're thinking about also is -I don't like to use the word "checklist," be cause everyone would be asking for the checklist -some type of a list of the kinds of things we're looking for that would be made available early on so that you could consider these standards or parameters before coming to the Agency. I would strongly recommend that before you begin any testing, you come in and explore the possibility or the concept of switching a particular class of drugs.
Cooley:
Let's talk about the 80 drugs switched in Denmark to OTC. "What is the meaning of this? Could you explain what happened and why it happened and how does it affect the United States?"
Gilbertson: There is a list of drugs-wellknown Rx drugs marketed in this country which have not only been proposed for switch in Denmark but are switched now. In this case, it's a cost-saving mechanism by the Danish government. That's one of the things that's been discussed. We must bear in mind that in those countries like Denmark there are more than two classes of drugs, so the regulatory standards are somewhat different. We're the only coun try that I know in the world that has only two classes -one or the other. Australia has five; I think Denmark must have three or four. So those things are taken into con sideration when drugs are switched.
Cooley: "Dr. Palmer, you talked about continuing education, school student edu cation, pharmacists' education. What mechanisms could be used in order, to im prove the OTC messages to pharmacists and make them more understandable?" Dr Henry A. Palmer: What mechanisms could manufacturers use to reach pharma cists? I think you could look at, for want of a better term, a model of what prescrip tion drug manufacturers do in terms of creating educational programs. It's been one of my goals to develop what I would call a model OTC industry support pro gram for schools of pharmacy which would peripherally, impact on continuing education programs for pharmacists as well as undergraduate education pro grams. In my experience in teaching OTCs, I get erratic responses when I solic it information from the industry. The model I envision is one that I hope the industry would consider as a means to see how easy it can be to cooperate with schools, who can provide the message to pharmacists and to undergraduate stu dents.
Cooley: "Dr. Gilbertson, is there any rea son why ibuprofen could not be in the in ternal analgesic monograph?" Gilbertson: Well, at the moment, the re cord's open until November 1989, for somebody to come forward and submit persuasive comments that it be included. It has been used now for several years, widely used, and in my opinion is a strong candidate. But those kinds of things have to be assessed.
Hank, "Can you suggest how we could get consumers aware of the impend ing switches before they occur? Is there a legitimate means so that they can be pre pared and learn more about the drugs be fore they're actually switched?" Palmer: Well, I recognize that some com panies in their advertising are now prim ing consumers for switch. They are doing that because the drugs involved are per haps likely switch candidates. Because it's so uncertain as to when switch will be finalized, I think you run the risk of get ting people excited about something that you can't deliver, so I don't know if manu facturers are going to invest any resources in that ahead of time. It may well be that consumer-oriented organizations might do that -organizations involved in pro mulgating self-care. In fact, probably some of those self-care guides that I re ferred to need to be re-written in view of switches that have occurred and those that will occur.
Cooley: Speaking of organizations other than manufacturers, another questioner would like to know, "What's the quality control for information coming to con sumers but not from manufacturersthrough other groups? Who will make sure that that's accurate?" Palmer: You have quality controls, and you've got the FTC looking at advertising and the FDA looking at labeling, but we have the first amendment that says "No one can look at what I write." That's a major problem with health care provid ers-when consumers reading about selfcare or even about prescription drugs as well as OTC drugs in consumer-oriented publications, and what they're reading might be contrary to their physician's or pharmacist's views on that particular sub ject. It can make for difficult patient-phy sician relations. But short of censorship, I don't know what can be done. As I recall from my student days, there were some classic cases where books were exhibited in juxtaposition to products, and in that context, those books were considered as labeling, and there was some challenge of the propriety of that. But as far as quali ty-I'm not certain how we can do it. I think it's difficult enough for physicians to keep up with what their patients are reading in the lay press, let alone be con cerned about the quality of it. You've go to know what they're being exposed to. Some drug companies as a matter of fact, provide that as a service by excerpting lay literature.
